OHSU research drives FDA approval for novel use of anemia drug in brain cancer imaging

OHSU lab started exploring new use of the drug 30 years ago; now, it may improve techniques to measure, monitor aggressive brain tumors

By Nicole Rideout December 17, 2025 Portland, Oregon

Lea esta página en español

Downloads

Rochelle Fu, Ph.D. (OHSU)

Lisa Muir, M.P.A., H.A., C.C.R.P. (OHSU)

Leslie Muldoon, Ph.D. (OHSU)

Laszlo Szidonya, M.D., Ph.D. (OHSU)

OHSU research drives FDA approval for novel use of anemia drug in brain cancer imaging 3

From left: Amy Huddleston, Lisa Muir, Rochelle Fu, Ramon Barajas, Leslie Muldoon, and Laszlo Szidonya. (OHSU/Christine Torres Hicks)

OHSU research drives FDA approval for novel use of anemia drug in brain cancer imaging 2

Researchers with OHSU’s Neuro-Oncology Blood-Brain Barrier Program supported several clinical trials investigating a novel use of a drug for brain cancer imaging; the data helped achieve its recent FDA-approval. (OHSU/Christine Torres Hicks)

OHSU research drives FDA approval for novel use of anemia drug in brain cancer imaging-2

Edward Neuwelt, M.D. (OHSU)

Ramon Barajas, Jr., M.D. (OHSU)

Travis Cook, M.S., M.B.A. (OHSU)